Research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-09. Anything still debated is marked as such rather than presented as settled.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
It was also found that 48Ca and 58Fe projectiles had a similar yield for the fusion-fission pathway, suggesting possible future use of 58Fe projectiles in making superheavy elements. It has also been suggested that a neutron-rich flerovium isotope can be formed by quasifission (partial fusion followed by fission) of a massive nucleus. Recently it has been shown that multi-nucleon transfer reactions in collisions of actinide nuclei (such as uranium and curium) might be used to make neutron-rich superheavy nuclei in the island of stability, though production of neutron-rich nobelium or seaborgium is more likely. Theoretical estimates of alpha decay half-lives of flerovium isotopes, support the experimental data. The fission-survived isotope 298Fl, long expected to be doubly magic, is predicted to have alpha decay half-life ~17 days. Making 298Fl directly by a fusion–evaporation pathway is currently impossible: no known combination of target and stable projectile can give 184 neutrons for the compound nucleus, and radioactive projectiles such as 50Ca (half-life 14 s) cannot yet be used in the needed quantity and intensity.
==== Symbolic AI and its limits ==== Symbolic AI (or "GOFAI") simulated the high-level conscious reasoning that people use when they solve puzzles, express legal reasoning and do mathematics. It was highly successful at some "intelligent" tasks such as algebra or IQ tests. In 1976, Newell and Simon proposed the physical symbol systems hypothesis: "A physical symbol system has the necessary and sufficient means of general intelligent action." However, the symbolic approach failed on many tasks that humans solve easily, such as learning, recognising an object or commonsense reasoning. Moravec's paradox is the discovery that high-level "intelligent" tasks were easy for AI, but low level "instinctive" tasks were extremely difficult. Philosopher Hubert Dreyfus had argued since the 1960s that human expertise depends on embodied, situational know-how that is not representable as explicit symbolic rules rather than conscious symbol manipulation, and on having a "feel" for the situation, rather than explicit symbolic knowledge. Although his arguments had been ridiculed and ignored when they were first presented, eventually, AI research came to agree with him. The issue is not resolved: sub-symbolic reasoning can make many of the same inscrutable mistakes that human intuition does, such as algorithmic bias.
Instances of users abusing software to generate controversial statements in the vocal style of celebrities, public officials, and other famous individuals have raised ethical concerns over voice generation AI. In response, companies such as ElevenLabs have stated that they would work on mitigating potential abuse through safeguards and identity verification. Concerns and fandoms have spawned from AI-generated music. The same software used to clone voices has been used on famous musicians' voices to create songs that mimic their voices, gaining both tremendous popularity and criticism. Similar techniques have also been used to create improved quality or full-length versions of songs that have been leaked or have yet to be released.
Sources: en.wikipedia.org
Coller (1966), father of Abciximab, vice president and physician-in-chief at Rockefeller University Peter Gray (1966), psychologist; professor at Boston College Brian Weiss (1966), psychiatrist noted for his research on reincarnation and past life regression Richard Axel (1967), winner of the Nobel Prize in Physiology or Medicine for studying the operations of the olfactory system Nai Phuan Ong (1967), professor of Physics at Princeton University Nick Scoville (1967), professor of astronomy at California Institute of Technology Robert Wald (1968), theoretical physicist at the University of Chicago Sidney R. Nagel (1969), University of Chicago physicist specializing in the complex physics of everyday materials Thomas B. Kornberg (1970), biochemist who was the first to purify and characterize DNA polymerase II and DNA polymerase III Harold J. Vinegar (1970), former chief scientist for physics of Shell plc, professor at Ben-Gurion University of the Negev Franklin G. Miller (1971), bioethicist at the National Institutes of Health Eric Rose (1971), cardiothoracic surgeon known for performing the first successful paediatric heart transplant; former president of the International Society for Heart and Lung Transplantation Paul S. Appelbaum (1972), psychiatrist credited with conceptualizing the idea of therapeutic misconception Steven M. Bellovin (1972), professor of computer science at Columbia University and chief technologist of Federal Trade Commission Rick L.
=== Incubator Lab Facility Investment === When SHIELD Illinois consolidated its labs into two University-owned and operated facilities to optimize logistics during the 2021-2022 school year. The Incubator Lab Facility on the University of Illinois Chicago (UIC) campus, the building where SHIELD Illinois's NextGen sequencing and innovation lab was located, was not originally built to meet the criteria of a CLIA-certified clinical diagnostics lab. So, the program decided to invest in upgrading the facility to bring it up to modern standards. According to Len Musielak, SHIELD Illinois Senior Director of Operations, SHIELD wanted to not only upgrade the building for its purposes but also add in ways that would provide a benefit to other tenants now and far into the future. The project included $2.2 million in upgrades and had a six-week deadline to complete the most difficult tasks and make the lab operational. Facility upgrades included:
There are two commonly cultivated strains which are known to be distinct. One is the strain that was collected in 1962 by ecologist and psychologist Sterling Bunnell (the Bunnell strain), colloquially mis-attributed as the Wasson-Hofmann strain. The other was collected from Huautla de Jiménez in 1991 by anthropologist Bret Blosser (the Blosser or Palatable strain). There are other strains that are not as well documented, such as the Luna strain (possibly Bunnell) isolated from a Hawaiian patch of Salvia divinorum clones, featuring unusually serrated and rounded rather than ovate leaves.
Sources: en.wikipedia.org
The Bio-medical Waste (Management and Handling) Rules, 1998 and further amendments were passed for the regulation of bio-medical waste management. On 28 March 2016 Biomedical Waste Management Rules (BMW 2016) were also notified by Central Govt. Each state's Pollution Control Board or Pollution control Committee will be responsible for implementing the new legislation. New regulations affect the distribution of medical waste by medical professionals into their proper receptacles. Due to the competition to improve quality and so as to get accreditation from agencies like ISO, the NABH, JCI, and many private organizations have initiated proper biomedical waste disposal but still the gap is huge. Many studies took place in Gujarat, India regarding the knowledge of workers in facilities such as hospitals, nursing homes, or home health. It was found that 26% of doctors and 43% of paramedical staff were unaware of the risks related to biomedical wastes. After extensively looking at the different facilities, many were undeveloped in the area regarding biomedical waste. The rules and regulations in India work with The Bio-medical Waste (Management and Handling) Rules from 1998, yet a large number of health care facilities were found to be sorting the waste incorrectly. The National Green Tribunal (NGT) has been stringent on the application of the BMW 2016 over the past 12 months. There are now over 200 licensed Common Bio Medical Waste Treatment and Disposal Facilities (CBWTDF) or Common Treatment Facility (CTF) in the country.
Aerosol mass spectrometry has also found its way into the field of pharmaceutical aerosol analysis, due to its ability to provide real-time measurements of particle size and chemical composition. People who suffer from chronic respiratory disease commonly receive their medication through the use of either pressurized metered dose inhaler (pMDI) or dry powder inhaler (DPI). In both methods the drug is delivered directly into the lungs by inhalation. In recent years, inhaled products have become available which deliver two types of drug within a single dose. Research has shown that the two drugs inhalers provide an enhanced clinical effect beyond that achieved when the two drugs are administered concurrently from two separate inhalers. It was determined using an AToFMS that the respirable particles in a DPI product and pMDI product were composed of co-associated active pharmaceutical ingredients, which is the reason behind the increased effects of the two drug inhalers.
== Contraindications == Caution is required in patients having closed angle glaucoma and in patients with a predisposition to urinary retention as the medication exhibits a relatively small anticholinergic effect. Dose adjustment is required in people who have chronic kidney disease. Liver injury has also been reported. Pizotifen treatment should be discontinued if there is any clinical evidence of liver dysfunction during treatment. Caution is advised in patients having a history of epilepsy. Withdrawal symptoms like depression, tremor, nausea, anxiety, malaise, dizziness, sleep disorder and weight decrease have been reported following abrupt cessation of pizotifen. Pizotifen is contraindicated in patients who suffer from hypersensitivity to any of its components or have gastric outlet obstruction, angle-closure glaucoma, and difficulty urinating. In addition, women who are pregnant should not take pizotifen.
=== Distribution in plants === Didymin is found in a variety of citrus fruits, including mandarin oranges, sweet oranges, grapefruit, and lemons, as well as in Origanum vulgare (oregano). In immature dropped fruits of Citrus sinensis, didymin has been quantified alongside other flavanone glycosides such as hesperidin and narirutin, with its content being better preserved by freeze-drying than by hot-air oven drying. It was first identified in grapefruit as a tasteless rutinoside-type flavanone glycoside, in contrast to the bitter neohesperidoside-type glycosides such as naringin. It is also present in chenpi (dried citrus peel), a traditional ingredient in Chinese medicine.
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.